Edition:
United Kingdom

Flex Pharma Inc (FLKS.OQ)

FLKS.OQ on NASDAQ Stock Exchange Global Market

0.48USD
8:59pm GMT
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$0.48
Open
$0.49
Day's High
$0.50
Day's Low
$0.46
Volume
140,031
Avg. Vol
230,464
52-wk High
$8.95
52-wk Low
$0.40

Latest Key Developments (Source: Significant Developments)

Flex Pharma Q3 Loss Per Share $0.15
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Flex Pharma Inc ::FLEX PHARMA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.15.Q3 REVENUE $251,000.  Full Article

Flex Pharma Estimates Up To ~$2.3 Mln In Restructuring Costs Plus Prior Disclosed Costs
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Flex Pharma Inc ::FLEX PHARMA-ESTIMATES WILL INCUR COSTS UP TO ABOUT $2.3 MILLION RELATED TO RESTRUCTURING IN ADDITION TO PRIOR DISCLOSED ONE-TIME TERMINATION BENEFIT COSTS.  Full Article

Flex Pharma Engaged Investment Banking Firm To Assist With Consideration Of Strategic Alternatives For Co's Hotshot Consumer Product Business‍​
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Flex Pharma Inc ::FLEX PHARMA - ENGAGED INVESTMENT BANKING FIRM TO ASSIST WITH CONSIDERATION OF STRATEGIC ALTERNATIVES FOR CO'S HOTSHOT CONSUMER PRODUCT BUSINESS‍​.  Full Article

Flex Pharma Q3 loss per share $0.54
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Flex Pharma Inc ::Flex Pharma reports third quarter 2017 financial results.Q3 loss per share $0.54.Q3 revenue $414,000 versus I/B/E/S view $477,000.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.Flex Pharma Inc - ‍expects to have sufficient capital to fund operations into early 2019​.  Full Article

Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Flex Pharma Inc :Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS.Flex Pharma - ‍data from exploratory phase 2 trial of FLX-787 showed statistically significant reduction in cramp-associated pain intensity & stiffness​.Flex Pharma Inc - ‍FLX-787 was generally well tolerated​.  Full Article

Flex Pharma initiates CMT phase 2 trial with FLX-787 in US
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Flex Pharma Inc :Flex Pharma initiates CMT phase 2 trial with FLX-787 in US.Flex Pharma Inc - ‍ALS phase 2 trial currently underway​.Flex Pharma Inc - ‍expects to report topline results from this study in middle of 2018​.  Full Article

Flex Pharma Q2 loss per share $0.51
Wednesday, 2 Aug 2017 

Aug 2 (Reuters) - Flex Pharma Inc :Flex Pharma reports second quarter 2017 financial results.Q2 loss per share $0.51.Q2 revenue $336,000.Q2 revenue view $515,000 -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Flex Pharma Inc - expects to have "sufficient" capital to fund its operations into early 2019.  Full Article

Flex Pharma initiates ALS phase 2 trial with flx-787 in U.S.
Tuesday, 1 Aug 2017 

Aug 1 (Reuters) - Flex Pharma Inc :Flex Pharma initiates ALS phase 2 trial with flx-787 in us.Says expects to report topline results from this study in middle of 2018.Says also intends to initiate a phase 2 clinical trial in cmt this quarter.  Full Article

Flex Pharma names William Mcvicar president and chief executive officer
Monday, 31 Jul 2017 

July 31 (Reuters) - Flex Pharma Inc :Flex pharma names William Mcvicar president and chief executive officer.Flex Pharma Inc says are on track to initiate phase 2 clinical trials of flx-787 in both als and cmt this quarter in U.S..Flex Pharma Inc - appointed william mcvicar, ph.d. as president and chief executive officer of flex pharma.  Full Article

FDA grants fast track designation to Flex Pharma’s FLX-787
Tuesday, 25 Jul 2017 

July 25 (Reuters) - Flex Pharma Inc :FDA grants fast track designation to Flex Pharma’s FLX-787 for the treatment of severe muscle cramps associated with ALS.‍Phase 2 trials in ALS and CMT to commence in us this quarter​.‍Phase 2 trials in ALS and CMT to commence in us this quarter​.‍Prioritizing US phase 2 commend trial; exploratory Australian ALS study to end early​.  Full Article

Flex Pharma to scrap two mid-stage neuromuscular disease trials

U.S. drug developer Flex Pharma Inc said on Wednesday it plans to stop two ongoing mid-stage trials, testing its lead drug to treat neuromuscular diseases, following safety concerns.